<PAGE> 1
EXHIBIT (A)(10)
NEWS RELEASE H
PO Box 105250, Atlanta, GA 3034
(770) 981-9460
www.harland.net
FOR MORE INFORMATION, CONTACT:
Victoria P. Weyand, Vice President of Communications
770-593-5127
[email protected]
HARLAND GRANTED EARLY TERMINATION OF HART-SCOTT-RODINO
WAITING PERIOD FOR CONCENTREX ACQUISITION
ATLANTA (August 7, 2000) - John H. Harland Company (NYSE: JH) said today that
it received early termination of the 15-day waiting period for its acquisition
of Concentrex Incorporated (Nasdaq: CCTX) under the Hart-Scott-Rodino Antitrust
Improvements Act, which was confirmed by letter dated August 2, 2000.
As previously announced, Harland has commenced a tender offer for all of the
outstanding shares of Concentrex pursuant to an Agreement and Plan of Merger,
dated as of July 17, 2000 for $7.00 per share, net to seller, in cash. The
tender offer will expire at 12:00 midnight, New York City time, on Friday,
August 18, 2000, unless extended. The tender offer is subject to certain
conditions, including at least a majority of Concentrex's outstanding shares,
on a fully diluted basis, being tendered without withdrawal prior to the
expiration of Harland's offer.
This announcement is neither an offer to purchase nor a solicitation of an
offer to sell shares of Concentrex Incorporated. Harland has filed a tender
offer statement with the Securities and Exchange Commission (SEC) and
Concentrex has filed a solicitation/recommendation statement with respect to
the offer. Concentrex shareholders are advised to read the tender offer
statement regarding the acquisition of Concentrex referenced in this press
release, and the related solicitation/recommendation statement, including the
amendments to these documents which are expected to be filed with the SEC later
this week. The tender offer statement (including an offer to purchase, letter
of transmittal and related tender documents) and the
solicitation/recommendation statement contain important information which
should be read carefully before any decision is made with respect to the offer.
These documents will be made available to all stockholders of Concentrex at no
expense to them. These documents will also be available at no charge on the
SEC's web site at www.sec.gov.
###
<PAGE> 2
HARLAND GRANTED EARLY TERMINATION OF HART-SCOTT-RODINO
WAITING PERIOD FOR CONCENTREX ACQUISITION
AUGUST 7, 2000
PAGE TWO
ABOUT HARLAND
Atlanta-based John H. Harland Company (www.harland.net) is listed on the New
York Stock Exchange under the symbol "JH." Harland is a leading provider of
checks, financial software and direct marketing to the financial institution
market. Scantron Corporation (www.scantron.com), a wholly owned subsidiary, is
a leading provider of software services and systems for the collection,
management and interpretation of data to the financial, commercial and
educational markets.
ABOUT CONCENTREX INCORPORATED
Concentrex Incorporated, based in Portland, Oregon, is a leading provider of
technology-powered solutions to deliver financial services, including a broad
range of traditional software and services integrated with leading e-commerce
solutions that already enable its customers to serve more than 1 million home
banking customers. Concentrex serves over 5,500 financial institutions of all
types and sizes in the United States. Concentrex has major offices in 11
additional cities across the country. Its World Wide Web site is
www.concentrex.com.
This press release contains statements which may constitute "forward-looking
statements." These statements include statements regarding the intent, belief
or current expectations of John H. Harland Company, Concentrex Incorporated and
members of their respective management, as well as the assumptions on which
such statements are based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties and that actual results may differ materially from
those contemplated by such forward-looking statements. Reference is made to the
Risk Factors and Cautionary Statements of Harland's Form 10-K and Form 10-Q and
to Concentrex's Securities and Exchange Commission reports filed under the
Securities Exchange Act.
